Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2006 4
2007 4
2008 2
2009 2
2010 1
2011 1
2012 1
2014 1
2016 2
2017 4
2018 3
2019 3
2020 1
2021 3
2022 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Corrigendum to "A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer" [Bioorgan. Chem. 119 (2022) 105505].
Lier S, Sellmer A, Orben F, Heinzlmeir S, Krauß L, Schneeweis C, Hassan Z, Schneider C, Schäfer A, Pongratz H, Engleitner T, Öllinger R, Kuisl A, Bassermann F, Schlag C, Kong B, Dove S, Kuster B, Rad R, Reichert M, Wirth M, Saur D, Mahboobi S, Schneider G. Lier S, et al. Among authors: sellmer a. Bioorg Chem. 2024 May;146:107248. doi: 10.1016/j.bioorg.2024.107248. Epub 2024 Mar 7. Bioorg Chem. 2024. PMID: 38458892 No abstract available.
A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer.
Lier S, Sellmer A, Orben F, Heinzlmeir S, Krauß L, Schneeweis C, Hassan Z, Schneider C, Patricia Gloria Schäfer A, Pongratz H, Engleitner T, Öllinger R, Kuisl A, Bassermann F, Schlag C, Kong B, Dove S, Kuster B, Rad R, Reichert M, Wirth M, Saur D, Mahboobi S, Schneider G. Lier S, et al. Among authors: sellmer a. Bioorg Chem. 2022 Feb;119:105505. doi: 10.1016/j.bioorg.2021.105505. Epub 2021 Nov 20. Bioorg Chem. 2022. PMID: 34838332 Free article.
Identification of a highly efficient dual type I/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells.
Beyer M, Henninger SJ, Haehnel PS, Mustafa AM, Gurdal E, Schubert B, Christmann M, Sellmer A, Mahboobi S, Drube S, Sippl W, Kindler T, Krämer OH. Beyer M, et al. Among authors: sellmer a. Cell Chem Biol. 2022 Mar 17;29(3):398-411.e4. doi: 10.1016/j.chembiol.2021.10.011. Epub 2021 Nov 10. Cell Chem Biol. 2022. PMID: 34762849 Free article.
Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3.
Wachholz V, Mustafa AM, Zeyn Y, Henninger SJ, Beyer M, Dzulko M, Piée-Staffa A, Brachetti C, Haehnel PS, Sellmer A, Mahboobi S, Kindler T, Brenner W, Nikolova T, Krämer OH. Wachholz V, et al. Among authors: sellmer a. Arch Toxicol. 2022 Jan;96(1):177-193. doi: 10.1007/s00204-021-03174-1. Epub 2021 Oct 19. Arch Toxicol. 2022. PMID: 34665271 Free PMC article.
A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.
Sellmer A, Pilsl B, Beyer M, Pongratz H, Wirth L, Elz S, Dove S, Henninger SJ, Spiekermann K, Polzer H, Klaeger S, Kuster B, Böhmer FD, Fiebig HH, Krämer OH, Mahboobi S. Sellmer A, et al. Eur J Med Chem. 2020 May 1;193:112232. doi: 10.1016/j.ejmech.2020.112232. Epub 2020 Mar 13. Eur J Med Chem. 2020. PMID: 32199135
28 results